Shots:
The companies collaborated to supply Tpoxx to support KaliVir’s oncolytic vaccinia immunotherapy platform & deliver new levels of assurance to physicians, regulators & patients with exciting experimental therapies
The platform has a no. of exclusive genetic alterations that can be coupled to create a special oncolytic virus that has been optimized for systemic absorption and anti-tumor immune activation
In preclinical studies, Tpoxx was active against most orthopoxviruses, including vaccinia. In 2021, SIGA & Bioarchitech collaborated to investigate Tpoxx when combined with Bioarchitech’s oncolytic vaccinia-based immunotherapy technology, would allow for greater doses of vaccinia vectors
Ref: GlobalNewswire | Image: SIGA
